+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05266846

Phase II Study of Pembrolizumab with Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy Alone in Advanced ALK-rearranged Lung Adenocarcinoma After Alectinib Failure

Led by Hunan Province Tumor Hospital · Updated on 2024-05-30

78

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of Pembrolizumab, Bevacizumab, and chemotherapy in people with advanced lung adenocarcinoma that has a specific ALK gene rearrangement and has not responded to first-line treatment with Alectinib. This phase II, open-label study is conducted at multiple centers and aims to see if this combination can improve progression-free survival in these patients. Eligible patients must have stage IV adenocarcinoma with persistent 5ALK mutation confirmed by genetic testing and meet physical requirements to receive the treatments. Participants will be randomly assigned to one of two groups one receiving Pembrolizumab 200 mg intravenously every three weeks plus Bevacizumab 15 mgkg and chemotherapy Pemetrexed 500 mgm2 and Carboplatin for up to four cycles, followed by maintenance therapy with Pembrolizumab, Bevacizumab, and Pemetrexed for up to 31 cycles or until disease progression or other reasons for stopping. The other group receives Bevacizumab plus chemotherapy without Pembrolizumab. Samples will be collected for advanced molecular testing to evaluate the tumor environment and predict treatment response. During the study, participants will undergo regular evaluations including imaging scans to measure tumor response and monitor side effects. Researchers will track progression-free survival as the primary outcome over two years, along with objective response rate and disease control rate. Safety and tolerability will be closely monitored throughout treatment. The total duration of participation varies depending on treatment response, progression, or participant decision. The study began in May 2024 and is expected to continue until February 2027.

CONDITIONS

Brief Title

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

Research Team

Y

Yongchang C Zhang, MD

N

Nong C Yang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here